Leadless Cardiac Pacemakers Market By Type (Micra Transcatheter Pacing System, Nanostim Leadless Cardiac Pacemaker, Wireless Cardiac Simulation System) - Growth, Future Prospects, And Competitive Analysis, 2018 - 2026

The leadless cardiac pacemakers market is set to reach from US$ 47.1 Mn in 2017 to US$ 269.8 Mn by 2026 representing outstanding growth at a compounded annual growth rate (CAGR) of 21.9% during the forecast period from 2018 to 2026. Atrial fibrillation is the most common type of cardiac arrhythmia diagnosed globally. As per the latest research citings of Global Burden of Disease (GBD) report the global prevalence rate of atrial fibrillation is 191.3 per 100,000 people. Leadless cardiac pacemakers are going to eventually replace the traditional pacemakers on account of its inherent features such as small size, less surgical complications, extended battery life, no device dislodgement and easy retrieval. Nanostim and wireless cardiac simulation systems will capture the market in the near future after FDA approval.

"Easy implantation, low device dislodgement and easy retrieval drive the micra transcatheter pacing system market growth"

Micra transcatheter pacing system (Medtronic, Plc.) are currently leading the type segment for leadless cardiac pacemakers market. It received succceful FDA approval in April 2016 owing to its inherent features such as easy implantation, low device dislodgement and easy retrieval. It is imbedded in the right ventricle via the femoral venous access which utilizes steerable delivery sheath. The nanostim leadless cardiac pacemaker system (St. Jude Medical, Inc.) was the first system to be implanted in humans for safety and efficacy studies during the LEADLESS clinical trial study. Recently it had 2 major recalls associated with premature battery failure and spontaneous detachment of the docking button. Both these system are limited to single chamber pacing specifically related to the ventricular pacing. In the near future dual chamber and multichamber pacing leadless systems will be critically studied in the clinical trial studies. Wireless cardiac simulation system (EBR Systems, Inc.) is still under investigation, it employs pulse generator which communicates with leadless pacing electrode via acoustic energy.

"Rising prevalence of cardiac arrhythmias and domicile of major players drive the market growth in North America"

Currently North America represents a share of 70% and is the global leader in leadless cardiac pacemakers market. As per the statistics provided by Center for Disease Control and Prevention (CDC), approximately 630,000 United States citizens die annually from heart disease which corresponds to 1 in every 4th individual. The primary features contributing towards its overwhelming growth are rising prevalence of cardiac arrhythmias and domicile of major players such as Medtronic, Plc., St. Jude Medical, Inc. and EBR Systems, Inc. etc. Europe holds a market share of 18% and is the second largest market in leadless cardiac pacemakers market. Rising public health awareness and affordable reimbursement scenario drive the market growth for leadless cardiac pacemakers in European region. Asia Pacific accounts for 7% market share majorly due to huge population base suffering with cardiac complications and developing healthcare infrastructure.

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by type and by geography.

Medical device manufacturers actively participating in the leadless cardiac pacemakers market are Boston Scientific Corporation, EBR Systems, Inc., Medtronic, Plc., Nanostim, Inc. and St. Jude Medical, Inc.

Key questions answered in this report

• Which major players are manufacturing leadless cardiac pacemakers?
• What is the disease etiology of cardiac arrhythmias and global prevalence rate of atrial fibrillation
• What is the patient population and market size for micra transcatheter pacing system?
• What will be the future market trends pertaining to leadless cardiac pacemakers market?
• What are the shortcomings of Nanostim and wireless cardiac simulation pacing system and when will they receive FDA approval?
• Which factors are responsible for the dominance of North America regional segment?